|
|
Vaccine Detail
|
Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007237
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: AFP
- AFP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Dendritic cells were harvested, washed, and pulsed separately with 10 μg/mL each of AFP peptide in serum-free RPMI 1640 for 1 to 2 hours, then washed and pooled (Butterfield et al., 2006).
- Description: A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with four alpha-fetoprotein (AFP) peptides, with potential immunostimulatory and antineoplastic activities. Upon administration, AFP peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against AFP-expressing cancer cells, resulting in tumor cell lysis. AFP is overexpressed in a variety of cancer cells. This vaccine has been used in trials involving hepatocellular carcinoma.(Butterfield et al., 2006; NCIT_C91378).
|
| Host Response |
|
|
| References |
Butterfield et al., 2006: Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(9); 2817-2825. [PubMed: 16675576].
NCIT_C91378: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91378]
|
|
